Sales of Merck’s drug Keytruda have grown beyond those of Bristol-Myers Squibb’s Opdivo, to become the global leading PD-1 inhibitor.
List view / Grid view
Filter the results
Levo Therapeutics has received Fast Track Designation from the FDA for LV-101 (intranasal carbetocin) for the treatment of Prader-Willi syndrome.
A study evaluating the efficacy and safety of vericiguat, a treatment for patients with worsening chronic heart failure, has met the primary efficacy endpoint.
A document from the DHSC has reportedly advised NHS doctors to ration certain medicines after outlining dozens of drugs that are in shortage, as published in a report.
Adakveo has been approved by the FDA to reduce the frequency of vaso-occlusive crisis, a painful complication of sickle cell disease.
The EMA CHMP has revealed its suggestion to grant marketing authorisation to seven medicines after its most recent meeting.
The dose CMO industry is performing strongly despite challenges of increasingly complex drug production, says a new report.
The ABPI’s Manifesto for Medicine has been issued, calling upon the next government in the UK to work closely with the pharma industry to increase innovation and access to medicines.
Scientists have created a new microparticle-based platform that can preserve, protect and deliver micronutrients which could help treat micronutrient deficiencies in developing countries.
A methodology has been developed which characterises how drugs influence each other when combined during treatment and sheds new light on how drugs perturb the underlying molecular networks.
Scientists have discovered that liposomes can translocate through the blood brain barrier following stroke and may be able to get drugs to the lesions to stop further damage.
A new report has said the majority of the active ingredients used in pharmaceuticals have never been evaluated for environmental risks.
Aurobindo has recalled prescription and over-the-counter ranitidine due to the medications containing unacceptable levels of NDMA.
New data shows the non-inferiority of efficacy for the subcutaneous (SC) formulation of CT-P13 to the intravenous (IV) formulation of CT-P13 in people with rheumatoid arthritis.
Specific batches of paracetamol tablets are being recalled as some pots have been found to contain discoloured tablets due to fungal contamination.